Target detail
EGFR
epidermal growth factor receptor
Data: Live structured evidence (Supabase)
Foundation row from public.targets — full Open Targets / ChEMBL preload remains a future operator job (Phase 8H+).
Display name: epidermal growth factor receptor
Aliases: EGFRvIII, EGFR, epidermal growth factor receptor
Type / organism: protein_coding · Homo sapiens
Source: opentargets · ENSG00000146648
Index freshness: last_synced_at 2026-05-15T17:48:44.125+00:00 · updated 2026-05-15T17:48:44.481941+00:00
Limitations & build flags
- Read-only structured navigator
- No clinical outcome benefit inferred
- Trial presence does not imply success
- Drug identity may require normalization
- Terminated/withdrawn trials must remain visible
This symbol is listed in public.targets (operator seed or future preload). Connector-backed sections below may still show empty states until ChEMBL / Open Targets / ClinicalTrials.gov mirror rows exist for this marker.
Connectors represented in loaded rows for EGFR. Empty groups mean no matching rows — not a claim about biology or clinical use.
- ClinicalTrials.govLive when indexed
Registry mirror rows in clinical_trials when operators run the CT.gov enrichment CLI — browser never calls the registry directly.
- Open TargetsLive when indexed
Disease–target evidence rows when operators run enrich:opentargets (GraphQL from trusted scripts only).
Rows from disease_target_evidence for this symbol.
glioblastoma
literature · opentargets
Drug records tied via drug_targets — mechanistic linkage only.
No linked drug rows
When drug_targets and drugs rows exist for this symbol, they are listed here.
disease_drug_evidence rows on linked drugs whose evidence_type suggests approved-elsewhere discussion context.
No matching rows
Import repoDB-compatible disease–drug evidence or add structured rows to surface discussion candidates here.
Mirror rows whose text fields mention this symbol — registry context only.
NCT00104091 — Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT06072586 — A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions
Status: RECRUITING · clinicaltrials.gov
Open trials hubNCT03603379 — Doxorubicin-loaded Anti-EGFR-immunoliposomes (C225-ILs-dox) in High-grade Gliomas
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT02664363 — EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma
Status: TERMINATED · clinicaltrials.gov
Open trials hubNCT03618667 — GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT04590664 — Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma
Status: RECRUITING · clinicaltrials.gov
Open trials hubNCT06973096 — CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy
Status: RECRUITING · clinicaltrials.gov
Open trials hubRepurposing signal rows for drugs linked to this target via drug_targets.
No research signals for linked drugs
Run the deterministic signal builder after drug_targets and source rows are present.
Structured rows with negative evidence_direction on disease–drug or signal tables.
No negative-direction rows
When structured evidence includes explicit negative direction fields, they surface here for oncology review.
- clinicaltrials.gov: 7
- opentargets: 1
Structured evidence rows link this marker to cohort contexts when ingested — interpret as research context only.
Disease contexts
0
Linked drugs
0
Linked in dataset
0
Research signals
0
Doctor-discussion candidate and related tags are descriptive only.
Signals list: Live structured evidence (Supabase)
No matching live evidence found
When repurposing_signal rows reference this marker via linked drugs, summaries appear here.